Patenting of embryonic stem cell procedures found unethical

27 March 2011

European researchers who use HES cell lines are worried that, if supported the Grand Chamber, this position will make regulators in European countries maintain or adopt correspondingly conservative positions. Similarly, it would call into question the validity of earlier human stem cell patents and potentially discourage investment in this area of research. However, HES cell research raises significant ethical concerns, and so it is not surprising to see related forms of patenting produce similar objections. 

More from us

Genomics and policy news